The FDA's database lists a supplement dated 25 September to the biologics licence for adalimumab-aqvh, an adalimumab biosimilar. The record names the product and licence holder but not what the supplement covers.
Biosimilar supplements commonly concern manufacturing, presentation or labelling — including interchangeability designations or new strengths. The entry alone does not say which. Until the label is updated, there is no change to prescribing.
For IBD teams, any switch between adalimumab products remains a decision to make with the patient, with a clear plan for monitoring response, drug levels where available, and injection technique with a new device.
- The 25 September entry is a supplement to an adalimumab biosimilar licence; the change is not specified.
- No new safety signal is indicated by the record.
- When switching adalimumab products, review device training and monitor response.
- Check the updated FDA label before assuming any change in interchangeability or presentation.
Why it matters
Biosimilar labelling changes can affect switching and pharmacy substitution in IBD clinics.
Don't overread it
A licence supplement is administrative until the label shows otherwise.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free